Pharmacological or genetic inhibition of ATM-dependent NF-κB pathway signaling reversed the upregulation of these cytokines and sensitized ALL cells to chemotherapeutics[19]. The gene discussed is ATM; the disease is acute lymphoblastic leukemia.